Dianthus Therapeutics, Inc. (DNTH) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune diseases. The company's lead product candidate, claseprubart, is a monoclonal antibody targeting the C1s complement protein, currently in Phase 2 and Phase 3 trials for Generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The company operates as a single segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $396 | $2,172 | $1,752 | $4,909 |
| Net Loss | $(36,765) | $(25,174) | $(97,905) | $(56,529) |
| Net Loss Per Share (Basic/Diluted) | $(0.97) | $(0.74) | $(2.68) | $(1.73) |
| Operating Expenses | $40,684 | $32,072 | $110,144 | $74,857 |
| Cash, Cash Equivalents & Investments | $555,489 (as of Sept 30, 2025) | |||
| Accumulated Deficit | $(272,297) (as of Sept 30, 2025) |
Liquidity: As of September 30, 2025, the company held $55.98 million in cash and cash equivalents and $499.50 million in marketable securities. Management expects these resources to fund operations into 2028.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased to $396,000 in Q3 2025 from $2.17 million in Q3 2024. This was driven by the cessation of related-party license revenue from Zenas BioPharma (now Tenacia) and a shift in the recognition of reimbursable costs under the new Tenacia License Agreement.
- Increased Operating Expenses: Operating expenses rose to $40.7 million in Q3 2025 from $32.1 million in Q3 2024.
- R&D Expenses: Increased by $7.0 million to $32.5 million, primarily due to higher clinical operation costs for claseprubart trials ($4.8 million increase) and licensing/milestone expenses ($2.0 million increase).
- G&A Expenses: Increased by $1.7 million to $8.2 million, driven by higher stock-based compensation ($1.1 million) and personnel costs ($0.6 million).
- Capital Raise: In September 2025, the company completed a public offering of 7.6 million shares and pre-funded warrants, generating gross proceeds of $288.4 million. This significantly bolstered the cash position compared to the prior year.
- Investment Income: Other income decreased to $3.5 million in Q3 2025 from $4.7 million in Q3 2024, attributed to lower average cash and investment balances in the current period compared to the prior year.
Guidance, Outlook, and Risks
- Clinical Progress:
- MaGic Trial (gMG): Announced positive top-line data in September 2025 showing rapid, statistically significant improvements over placebo for both 300mg and 600mg doses.
- CAPTIVATE Trial (CIDP): Interim responder analysis of the first 40 participants is anticipated in Q2 2026.
- MOMENTUM Trial (MMN): Top-line results are expected in the second half of 2026.
- New Asset Acquisition: On October 16, 2025 (subsequent event), the company entered into an exclusive license agreement with Nanjing Leads Biolabs for DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor. The deal includes up to $38.0 million in upfront and near-term milestones and potential future milestones totaling $962.0 million.
- Outlook: The company expects R&D and G&A costs to continue increasing significantly as it advances clinical trials. It does not expect to generate product revenue until regulatory approval is obtained.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional capital to fund operations, reliance on third-party manufacturers (CDMOs/CROs), and macroeconomic factors affecting the biotech sector.
Investor Verification Checklist
- Verify the sustainability of the cash runway into 2028 given the increased burn rate from expanded clinical trials.
- Confirm the timeline and criteria for the interim responder analysis in the CAPTIVATE Phase 3 trial (CIDP) scheduled for Q2 2026.
- Review the terms of the new DNTH212 license agreement, specifically the $38 million upfront/near-term payment structure and the $962 million potential milestone upside.
- Monitor the transition of revenue recognition from the Zenas/Tenacia agreements and the impact on future cash flows from cost reimbursements.
- Assess the dilution impact of the September 2025 public offering and the remaining capacity under the At-The-Market (ATM) program ($160.8 million).